Medigene Biotech (基亞生物科技; 3176 TT) announced that the oncolytic virus therapeutic OBP-301 (Telomelysin), co-developed with its Tokyo-listed strategic partner Oncolys BioPharma (4588 TYO), was officially granted manufacturing and marketing approval by Japan's Ministry of Health, Labour and Welfare (MHLW). The approved indication is designated for "Esophageal cancer unsuitable for curative resection or chemoradiotherapy." Because OBP-301 previously secured Orphan Drug Designation from Japanese regulatory authorities, the asset is legally granted a 10-year period of market exclusivity in Japan.

• Regulatory Classification: The MHLW's evaluation committee on Regenerative Medicine Products and Biotechnology issued a "General License" (通常承認; Normal/Standard Approval) for the therapeutic. This designation signifies that OBP-301 cleared rigorous review of its safety and efficacy metrics through complete clinical trial sets without requiring conditional or time-limited constraints (such as the conditional accelerated pathways often applied to regenerative assets in Japan).
• Post-Market Surveillance Requirements: Under the terms of the commercial approval, the co-developers will conduct a post-market surveillance study tracking an assigned cohort of 85 clinical cases to monitor long-term safety profiles.
• Commercial Architecture: Because Medigene Biotech co-funded the global research, development, and clinical trial expenses of OBP-301 alongside Oncolys BioPharma, both companies will proportionately share all future commercial revenues, licensing milestones, and net business profits derived from the therapeutic's global commercialization.

Resource:基亞與日廠 Oncolys 合作 OBP-301獲厚生勞動省核准上市